Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

NCT02976012
Conditions
Proliferative Diabetic Retinopathy
Interventions
Aflibercept, Endolaserless Vitrectomy
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

NCT01469156
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

NCT03340610
Conditions
Diabetic Macular Edema
Interventions
Alflibercept
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy

NCT00837330
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 0.3 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab

NCT01845844
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab 0.3mg/0.05cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Neovascular Polypoidal Choroidal Vasculopathy
Interventions
Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Augusta, Georgia